Resveratrol may dose-dependently modulate nephrin and OTULIN levels in a doxorubicin-induced nephrotoxicity model

Area of Science:

• Nephrology
• Pharmacology
• Biochemistry

Background:

• Doxorubicin (DOX) is a potent chemotherapeutic agent with significant nephrotoxicity as a major side effect.
• Understanding the molecular mechanisms of DOX-induced kidney damage and identifying protective agents is crucial for patient care.

Purpose of the Study:

• To investigate the protective effects of varying doses of Resveratrol (RSV) against Doxorubicin (DOX)-induced nephrotoxicity in a rat model.
• To determine if RSV exhibits antioxidative, anti-inflammatory, and anti-apoptotic properties in kidney tissue.
• To assess the impact of RSV on nephrin and OTULIN protein levels during DOX-induced nephrotoxicity.

Main Methods:

• A Sprague-Dawley rat model was used, divided into six groups: control, DOX, and DOX with different RSV doses (1 mg/kg/day and 5 mg/kg/day).
• Kidney tissues were analyzed biochemically, histologically, and immunohistochemically on day 15 post-treatment.
• Key markers of oxidative stress, inflammation, apoptosis, and specific proteins (nephrin, OTULIN) were evaluated.

Main Results:

• Doxorubicin administration led to decreased nephrin and OTULIN levels, accompanied by significant oxidative stress, inflammation, apoptosis, and histopathological damage in kidney tissue.
• Resveratrol treatment, particularly at the higher dose, effectively counteracted the DOX-induced alterations.
• RSV demonstrated dose-dependent antioxidant, anti-inflammatory, and anti-apoptotic effects, mitigating the observed nephrotoxicity.

Conclusions:

• Resveratrol exhibits significant nephroprotective effects against Doxorubicin-induced kidney damage.
• RSV's protective mechanisms involve modulating oxidative stress, inflammation, apoptosis, and potentially regulating nephrin and OTULIN levels.
• These findings suggest RSV as a promising therapeutic agent to mitigate chemotherapy-related nephrotoxicity.